Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
Argenx reported 18 consecutive quarters of revenue growth, with Q2 2026 sales up 60% year-over-year. Its therapies Vyvgart and Vyvgart Hytrulo are driving growth, with expanding operating margins. The company expects further growth from new indications and pipeline developments. Analysts rate it a buy, with a 14% upside target.
How this was made
The 30-second read
Why it matters
The new trial data adds a high‑impact catalyst that could accelerate revenue growth and justify higher valuation multiples.
Market read
Positive trial results for a mid‑cap biotech can trigger notable price moves and influence sector sentiment.
What to watch
Regulatory timelines and reimbursement uncertainty for the new indication could delay commercial upside.
Background
Argenx has delivered 18 quarters of revenue growth, driven by Vyvgart and its Hytrulo formulation, and is expanding its pipeline with multiple upcoming studies.
Ticker impact
Argenx announced positive late‑stage trial results for Vyvgart Hytrulo in autoimmune myositis, a new clinical win.
Potential short‑term price rally of 5‑10% as investors price in the new indication.
Clinical success in a rare disease adds a multibillion‑dollar opportunity and validates the platform, which historically moves biotech stocks sharply.
Market effects
Strengthens the autoimmune‑biologics sector and may boost peers with similar platforms.
U.S. biotech market gains confidence in late‑stage trial pipelines.
Highlights the potential of hybrid biologic‑delivery technologies worldwide.
Counterpoint
The stock may already be priced for growth; further data could disappoint, leading to a pull‑back.
Key entities
- CompanyArgenx
Biotech firm developing Vyvgart and pipeline candidates.
- ProductVyvgart Hytrulo
Hybrid biologic targeting severe autoimmune diseases.
